Oncology Corporate Profile
R-PHARM US was founded in 2014 with the goal of acquiring and commercializing products that help patients suffering from cancer and immunology conditions. R-PHARM's portfolio includes IXEMPRA, a chemotherapy agent approved for metastatic breast cancer, and a pipeline that includes molecules being developed for immunology and oncology indications.
|Ixempra®||ixabepilone||Ixempra® (ixabepilone), a microtubule inhibitor, in combination with capecitabine is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane. Ixempra® as monotherapy is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, andcapecitabine.|
|Brand / Product||Class||Area of Study||Phase||Partnership|
|RPH 002||monoclonal antibody||Various cancer types||III|
|RPH 001||monoclonal antibody||Various cancer types||III|
|RPH 203||RANKL inhibitor||Various cancer types||II|
View additional information on product candidates here »